“When I walked into the tech transfer, we were a million dollars over budget, six months behind schedule, and struggling to make a single successful batch,” says Amy Gamber. Amy Gamber, Executive Director, Lifecycle Lead at Kyverna Therapeutics, specializes in
Bora Pharmaceuticals Co., Ltd. has entered a strategic alliance with Corealis Pharma Inc. to provide a unified pathway for oral solid dose (OSD) drug development and manufacturing. The companies said the partnership is intended to simplify outsourcing and create a
ProBioGen has entered a collaboration with Spica Therapeutics to support cell line development for ST101, the biotechnology company’s first clinical candidate targeting immunosuppressive tumour-associated macrophages. The agreement outlines how the partners aim to advance Spica’s oncology programme through an integrated
Watch the presentation of the results with MasterControl
GlycoNex, Inc. has entered a CDMO service agreement with the Institute of Science Tokyo and Change Cure Co. to support the clinical advancement of CC001, an investigational anti-HMGB1 monoclonal antibody for frontotemporal lobar degeneration (FTLD). Under the agreement, GlycoNex will
Andelyn Biosciences has entered a partnership with Jaguar Gene Therapy to conduct late-stage Process Performance Qualification (PPQ) manufacturing for JAG201, an investigational gene therapy designed for SHANK3 haploinsufficiency and clinically diagnosed Phelan-McDermid syndrome (PMS). PMS is a leading monogenic cause
“I got a phone call from the French ambassador, and he said, ‘I need this product which you’re producing in your factory in Warsaw, in France, beginning in one week. We’re running out,’” recalls Markus Sieger, CEO of Polpharma Group,
Saya Biologics has announced a strategic partnership with Enzene Biosciences to support the development and manufacture of two biologic therapies for osteoporosis in Mexico. The agreement combines Enzene’s CDMO capabilities with Saya Bio’s role in registration, commercialisation and distribution of
SCTbio has formed a strategic collaboration with Fortrea to integrate GMP manufacturing and clinical development for cell and gene therapies. The companies stated that the partnership is designed to streamline development pathways, reduce programme complexity and support faster delivery of
Eckert & Ziegler has entered a supply agreement with SK Biopharmaceuticals to provide Actinium-225 (Ac-225) for the company’s radiopharmaceutical research and development activities. SK Biopharmaceuticals, based in South Korea, is expanding its oncology pipeline with programmes focused on central nervous
